The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Cellectar; YmAbs Therapeutics Inc
Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).
 
Jennifer Foster
No Relationships to Disclose
 
Joel M. Reid
No Relationships to Disclose
 
Charles G. Minard
No Relationships to Disclose
 
Emasenyie Isikwei
No Relationships to Disclose
 
Xiaowei Liu
No Relationships to Disclose
 
Stacey L. Berg
Travel, Accommodations, Expenses - nonprofit
Other Relationship - Children's Oncology Group; Pediatric Early Phase Clincial Trials Network
 
Sarah Garrett Injac
Research Funding - Takeda
 
Elizabeth Fox
Other Relationship - Helsinn Therapeutics
 
Brenda Weigel
No Relationships to Disclose